Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Inactine: VITX will begin in 3Q02 a double-blind U.S. Phase III study of Inactine in 200 cardiovascular surgery patients requiring acute red blood cell transfus

V.I. Technologies Inc. (VITX), Watertown, Mass.
Product: Inactine

Read the full 88 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE